Quick Answer
Aspire Biopharma Holdings, Inc. reported Net Income Loss of -$24.48 million for the year ending 2025.
- Aspire Biopharma Holdings, Inc. showed a decrease of -1,768.9% in Net Income Loss from 2024 to 2025.
- This data is from Aspire Biopharma Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2021 to 2025), Aspire Biopharma Holdings, Inc.'s Net Income Loss has declined by 95,997.5%.
- Historical annual values: Fiscal year 2025: -$24.48 million | Fiscal year 2024: -$1.31 million | Fiscal year 2023: $4.46 million | Fiscal year 2022: $3.34 million | Fiscal year 2021: -$25.5 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: